Recent Updates
Recently added Catalysts
GEHC Positive Sentiment

GE HealthCare reports third quarter 2026 financial results

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GE HealthCare announced its third quarter 2026 financial results, showcasing strong growth. The company reported significant top-line growth and margin expansion across all segments. CEO Peter Arduini highlighted robust earnings per share growth and effective commercial execution. The results reflect improved performance and customer adoption of their innovations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong top-line growth reported
  • Margin expansion across all segments
  • Robust EPS growth in the third quarter
  • Increased customer adoption of innovations

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
2.9%
average across 3 past catalysts
Lead asset
PET MPI
Phase 3 · Coronary Artery Disease (CAD)

Full Press Release Details

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2026. GE HealthCare President and CEO Peter Arduini said, “We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter. This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations. With our improved performance year-to

Frequently Asked Questions

What were GE HealthCare's Q3 2026 financial results?

GE HealthCare reported strong top-line growth and margin expansion.

Who is the CEO of GE HealthCare?

Peter Arduini is the President and CEO of GE HealthCare.

What contributed to GE HealthCare's strong performance?

The performance was driven by commercial execution and customer adoption.

When did GE HealthCare report these results?

The results were reported for the third quarter ended September 30, 2026.

ShareAdd on Google
Tags: GEHC GE HealthCare financial results Q3 2026 earnings per share margin expansion
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$2079M liquidity · $0M/mo burn
Low dilution risk
Lead asset
PET MPIPhase 3
Coronary Artery Disease (CAD) →

Catalyst track record

+32%
best trade around GEHC's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for GEHC.

See every catalyst's timing & PoA →